ArticleCureus2025
Management Strategies for Hypercapnic Respiratory Failure in Chronic Obstructive Pulmonary Disease (COPD): A Case-Based Discussion.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hypercarbic respiratory failure due to chronic lung disease is common and presents significant challenges, especially as many patients have multiple comorbidities. Chronic obstructive pulmonary disease (COPD) is one of the leading causes. Patients with COPD and respiratory failure, whether acute or chronic, face worse prognoses. Managing exacerbations of chronic obstructive pulmonary disease (COPD) requires a personalized approach, taking into account the patient's specific clinical profile and comorbid conditions. High-flow nasal cannula (HFNC) therapy has been shown to prevent the need for intubation and may aid in the early extubation process. In patients with COPD who develop hypercapnic respiratory failure while in the intensive care unit (ICU), the decision between high-flow nasal oxygen (HFNO), noninvasive ventilation (NIV), and invasive mechanical ventilation should be made based on the severity of respiratory failure, the patient's overall health status, and individual characteristics. The selection of the appropriate ventilatory support method must also consider factors such as the degree of respiratory distress, blood gas abnormalities, and the presence of other underlying medical conditions that could influence the response to treatment. Each intervention has its indications, benefits, and limitations, and the optimal choice should be tailored to the patient's needs. Noninvasive ventilation (NIMV) has become this population's primary respiratory support method, though comfort issues can hamper patient compliance. High-flow nasal oxygen (HFNO) devices have emerged as a valuable alternative. This study presents cases illustrating the application of conventional NIMV, HFNO, and invasive ventilation in treating hypercarbic respiratory failure. Written consent was obtained from the patient's relatives for all procedures to be performed on all three patients after admission to the intensive care unit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.